Elevation of sodium levels in the cerebral ventricles of anaesthetized dogs triggers the release of an inhibitor of ouabain-sensitive sodium, potassium-ATPase into the circulation

1986 ◽  
Vol 70 (1) ◽  
pp. 103-110 ◽  
Author(s):  
Bhagavan S. Jandhyala ◽  
Ahmad F. Ansari

1. The present studies are designed to determine whether a ouabain-sensitive inhibitor of Na+, K+−stimulated ATPase is released into the circulation when the Na+ levels are elevated in the cerebral ventricles in pentobarbital anaesthetized dogs. Na+−pump activity was estimated in the plantar and dorsal branches of the lateral saphenous veins by using the 86Rb-uptake method. 2. Infusion of the cerebral ventricles with the artificial cerebrospinal fluid (CSF) containing normal Na+ (0.15 mol/l) for over 120 min resulted in significant increases in only ouabain-sensitive 86Rb-uptake. In contrast, when the ventricles were perfused with the CSF containing high Na+ (0.3 mol/l) for similar periods, there were significant reductions in the ouabain-sensitive as well as in ouabain-insensitive 86Rb-uptake by the blood vessels. 3. Similar blood vessels from a separate group of dogs were incubated for 120 min in the plasma samples collected from the above groups in which normal or hypertonic Na+ solutions were infused. The data showed that ouabain-sensitive 86Rb-uptake (but not the insensitive component) was significantly inhibited only in those vessels which were incubated in the plasma samples that were obtained at 120 min after perfusion of the cerebral ventricles with CSF containing high Na+ (0.3 mol/l). 4. These studies have provided direct evidence which would suggest that the elevation of Na+ levels in the cerebral ventricles would precipitate the release of an inhibitor of the ouabain-sensitive Na+−pump into the circulation, perhaps due to an activation of Na+−sensitive and/or osmo-sensitive sites in the circumventricular organs. It is hypothesized that this humoral substance may be the same ‘natriuretic hormone’ which is released after acute expansion of circulating blood volume.

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 2049-2049 ◽  
Author(s):  
S. DePrimo ◽  
B. Wu ◽  
S. Huang ◽  
R. Bautista ◽  
B. Cancilla ◽  
...  

2049 Background: XL184 is an oral inhibitor of MET, RET, KIT, and VEGFR-2 with potent antitumor effects in preclinical models of GBM. Clinically, elevated levels of MET, KIT, VEGFR-2, and VEGF-A are found in GBM, where MET and KIT levels correlate with poor prognosis. XL184–201 is a fully enrolled GBM study (N = 46) which mandated collection of archival tumors and serial plasma samples. The encouraging clinical activity of XL184 in this study is the subject of a separate abstract. Methods: Tumor profiling focused on genomic alterations prevalent in GBM, reflecting dysregulation of key signaling pathways (Nature 2008; 455:1061), or XL184 targets. Plasma samples were analyzed with ELISA assays. Correlation of results with clinical outcomes is a secondary objective of study XL184–201. Results: Tumor genotyping assessments included EGFR and KIT copy number; PTEN, PIK3CA, PIK3R1, and NF1 sequencing, as well as MGMT and PTEN promoter methylation. Results from the first 12 cases indicate sequence variations & frequencies similar to reports in the literature. IHC analysis of MET, RET, and VEGFR-2 protein expression was also performed. In ∼ 80% of samples, tumor cells stained positive for MET with a lower fraction positive for RET and VEGFR-2 in tumor cells (42% and 58%, respectively). RET and VEGFR-2 expression was often seen in tumor-associated blood vessels, while MET signal in blood vessels was more limited (33%). Preliminary biomarker analysis established significant modulation of plasma levels of VEGF-A, sMET, sVEGFR-2, sKIT, and PlGF, consistent with multiple on target effects. Objective response was observed in the presence or absence of tumor EGFR amplification, PTEN mutation, and MGMT promoter methylation. The potential predictive value of these and other biomarkers is under investigation. Conclusions: Plasma biomarkers confirm pharmacodynamic activity of XL184 in advanced GBM where marked clinical activity has been observed. Upon completed analysis of a full set of biological samples and with mature clinical data, predictive markers for clinical activity of XL184 will be evaluated. [Table: see text]


1980 ◽  
Vol 59 (s6) ◽  
pp. 203s-205s ◽  
Author(s):  
M. J. Mulvany ◽  
N. Nyborg ◽  
H. Nilsson

1. We have investigated the noradrenaline-activated calcium sensitivity of 150 μm mesenteric resistance blood vessels from spontaneously hypertensive and control Wistar-Kyoto rats. 2. Under control conditions the spontaneously hypertensive rat blood vessels had a greater calcium sensitivity than the Wistar-Kyoto rat vessels. 3. In the presence of 1 mmol of ouabain/l, a treatment known to inhibit the sodium-potassium-dependent ATPase, the responses of the spontaneously hypertensive rat blood vessels were reduced more than those of the Wistar-Kyoto rat blood vessels, so that the responses of spontaneously hypertensive rat and Wistar-Kyoto rat blood vessels were then similar. 4. Similar results were obtained by removing external potassium, a procedure which should also inhibit the sodium-potassium-ATPase. 5. The results suggest that the greater noradrenaline-activated calcium sensitivity of spontaneously hypertensive rat blood vessels may be associated with an increased sodium-potassium-ATPase activity.


1976 ◽  
Vol 51 (s3) ◽  
pp. 391s-394s
Author(s):  
J. S. Hutchinson ◽  
P. Schelling ◽  
J. Möhring ◽  
D. Ganten

1. Artificial cerebrospinal fluid was perfused through the cerebral ventricles of conscious rats. A basal secretion rate of 16 ± 3 × 10—15 mol of immunoreactive angiotensin 11/min was calculated for intact rats. 2. Most of the immunoreactive angiotensin II consisted probably of the heptapeptide or pentapeptide angiotensin II fragments. 3. The pressor responses to intraventricular perfusions of angiotensin II were normal in Long—Evans rats, virtually absent in rats homozygous for hereditary hypothalamic diabetes insipidus, irrespective of whether they were injected with vasopressin tannate or not, and intermediate in rats heterozygous for hypothalamic diabetes insipidus. 4. The results suggest that the pressor response to intraventricular angiotensin II is related to the release of vasopressin.


1984 ◽  
Vol 30 (10) ◽  
pp. 1703-1705 ◽  
Author(s):  
C I Bhagat ◽  
P Garcia-Webb ◽  
E Fletcher ◽  
J P Beilby

Abstract The osmolalities of 100 plasma samples were measured and compared with the osmolalities calculated from the plasma concentrations (mmol/L) of sodium, potassium, glucose, and urea by several different formulae. The formula recommended by Dorwart and Chalmers (Clin Chem 21: 190, 1975) gave inferior results to those obtained with our "most accurate" formula: osmolality = 1.89 Na + 1.38 K + 1.03 urea + 1.08 glucose + 7.45. We recommend using this formula for calculation of osmolality on equipment linked to a computer. However, for simplicity, and to reduce the possibility of calculation errors, the following formula can be used for manual calculations: osmolality = 1.86 (Na + K) + glucose + urea + 10.


2010 ◽  
Vol 340 (1) ◽  
pp. 159-168 ◽  
Author(s):  
Alan J. Wilson ◽  
Colin J. Carati ◽  
Bren J. Gannon ◽  
Rainer Haberberger ◽  
Tim K. Chataway

1995 ◽  
Vol 05 (01) ◽  
pp. 27-32 ◽  
Author(s):  
I. SATO ◽  
N. MATSUSAKA ◽  
H. KOBAYASHI ◽  
T. SUZUKI ◽  
K. SERA ◽  
...  

Ca-DTPA and Zn-DTPA were injected intraperitoneally into rats with a dose of 30 or 300 µmol/kg. The blood was collected from the tail vein just before the injection, 3, 6 and 24 hours after the injection. and centrifuged 10 separate the plasma. These plasma samples were analyzed by PIXE at Nishina Memorial Cyclotron Center. Sodium, potassium, calcium, iron, copper and zinc were detected in the plasma. Ca-DTPA significantly lowered the concentration of zinc, while no significant changes were observed in the other metals. Zn-DTPA did not lower any metal concentrations, but a significant increase of plasma zinc was observed. In conclusion, Ca-DTPA was confirmed to induce hypozincemia, which may be the cause of fetal injuries such as abortion, fetal death and malformation. Zn-DTPA was suggested not to induce any deficiencies of essential metals.


1976 ◽  
Vol 38 (6) ◽  
pp. 48-52 ◽  
Author(s):  
H W Overbeck ◽  
M B Pamnani ◽  
T Akera ◽  
T M Brody ◽  
F J Haddy

1978 ◽  
Vol 234 (5) ◽  
pp. H582-H591 ◽  
Author(s):  
H. A. Kontos ◽  
E. P. Wei ◽  
A. J. Raper ◽  
W. I. Rosenblum ◽  
R. M. Navari ◽  
...  

The mechanism of action of hypoxia on cerebral blood vessels and its role in the regulation of the cerebral circulation were investigated in anesthetized cats. Arterial hypoxia produced marked cerebral arteriolar vasodilation, which was partially reversed by perfusing the space under the cranial window with artificial cerebrospinal fluid (CSF) containing 6-94% oxygen. More marked increase in the local supply of oxygen, via perfusion of the space under the cranial window with fluorocarbon FC-80 equilibrated with 100% oxygen, completely eliminated the vasodilation induced by arterial hypoxia. Fluorocarbon equilibrated with 100% N2 had no effect on the vasodilation. The vasodilation associated with hypotension was completely reversed by perfusion with fluorocarbon equilibrated with 100% oxygen and was unaffected by perfusion with fluorocarbon or CSF equilibrated with gas not containing oxygen. The vasodilation associated with Metrazole-induced seizures was partially reversed by perfusion with fluorocarbon containing oxygen. The results show that hypoxia dilated cerebral blood vessels entirely via a local mechanism, that hypoxia is the dominant mechanism involved in the vasodilation associated with hypotension, and that it is, at least partially, responsible for the vasodilation associated with seizures.


1983 ◽  
Vol 245 (1) ◽  
pp. R76-R82
Author(s):  
C. V. Gisolfi ◽  
P. T. Wall ◽  
W. R. Mitchell

In unanesthetized monkeys (4-8 kg), artificial cerebrospinal fluid (ACSF) containing excess (greater than 1.3 mM) amounts of Ca2+ was infused at 20 microliters/min for 5 min into the cerebral ventricles. Core and skin temperatures, respiratory gas exchange, heart rate, and sweat rate were monitored. At 22 degrees C, intracerebroventricular infusions of 13-39 mM Ca2+ produced a dose-related hypothermia associated with a dose-related fall in metabolic rate and heart rate and a rise in average skin temperature. General body sweating was not initiated, and respiratory water loss was unaffected; however, exercise activated sweating and elevated it from 0.05 to 0.22 mg X (cm2 X min)-1. At 35 or 40 degrees C, infusion of 26 mM Ca2+ failed to influence ongoing general body sweating; however, subsequent exercise increased sweat rate by 63%. Heart rate was unaffected. At 15 degrees C metabolic rate increased 50%. After infusing 26 mM Ca2+, metabolism decreased 6% and core temperature declined 0.8 +/- 0.24 degrees C. Skin temperatures continued to fall, heart rate fell, and sweating was not initiated. In contrast, infusing ACSF increased metabolism 11% and core temperature fell only 0.18 +/- 0.14 degrees C. The inability of exogenous Ca2+ to 1) initiate sweating at 22 degrees C, 2) elicit vasodilation at 15 degrees C, 3) initiate or stimulate sweating at 35 or 40 degrees C, or 4) lower core temperature at 35 or 40 degrees C argues against a set-point function for this cation.


Sign in / Sign up

Export Citation Format

Share Document